[ad_1]
When asked by the AFP news agency, the pharmaceutical giant said a batch of vaccine doses produced at Emergent BioSolutions’ Baltimore plant “did not meet quality standards.” It is true that the company did not confirm the exact batch number of the damaged vaccine.
Johnson & Johnson also noted that the batch of damaged doses “did not reach the final stages of the filling and manufacturing process.”
“Quality and safety will be our top priorities,” said the Johnson & Johnson report.
The US Food and Drug Administration said it was aware of the situation, but its representatives declined to comment.
Johnson & Johnson, for its part, said it would send more experts to the plant to “oversee, manage and support the production of Johnson & Johnson’s COVID-19 vaccine,” which is expected to allow customers to deliver an additional $ 24 million. in April. vaccine dose.
“We are still expecting that by 2021. By the end of the year we will deliver more than a billion. Doses of the COVID-19 vaccine,” says Johnson & Johnson.
